The GOG 240 trial established which regimen as standard first-line treatment for recurrent or metastatic cervical cancer?

• A Cisplatin + paclitaxel
• B Carboplatin + paclitaxel + pembrolizumab
• C Cisplatin + topotecan
• D Cisplatin + paclitaxel + bevacizumab ✓

Explanation

The GOG 240 trial (NEJM 2014) demonstrated that adding bevacizumab to chemotherapy (cisplatin or topotecan plus paclitaxel) significantly improved overall survival from 13.3 to 17 months in recurrent or metastatic cervical cancer. This established bevacizumab + chemotherapy as the standard first-line regimen for advanced/recurrent disease. Pembrolizumab was later added (KEYNOTE-826) for PD-L1 positive disease but this was a later development.

Reference: Shaw's Textbook of Gynaecology, 17th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.